{
  "schema_version": 1,
  "kind": "drug_profile",
  "generic": "cabergoline",
  "review_status": "reviewed",
  "origin": "openfda",
  "sections": {
    "adult": [
      {
        "text": "( 2.1 ) Recommended starting dosage of cabergoline tablets is 0.25 mg orally twice weekly.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "( 2.2 ) Titrate cabergoline tablets to achieve normal serum prolactin levels by increasing cabergoline tablets by 0.25 mg orally twice weekly at intervals of no less than 4 weeks.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "( 2.2 ) Maximum recommended dosage is 1 mg orally, twice weekly.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'dosage and administration', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ],
    "child": [
      {
        "text": "Safety and effectiveness of cabergoline tablets in pediatric patients have not been established.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'pediatric use', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ],
    "renal": [
      {
        "text": "( 5.1 ) Pleural, Pulmonary and Retroperitoneal Fibrosis : During cabergoline tablets treatment monitor for signs and symptoms of progressive fibrosis, (e.g., pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular obstruction).",
        "source": "US FDA label for cabergoline (Cabergoline), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the loin/flank, lower limb edema, abdominal masses or tenderness that may indicate retroperitoneal fibrosis).",
        "source": "US FDA label for cabergoline (Cabergoline), section 'warnings and cautions', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ],
    "hepatic": [
      {
        "text": "Avoid use of cabergoline tablets for the inhibition or suppression of physiologic lactation [see Indications and Usage ( 1 ) and Warnings and Precautions ( 5 . 4 )] . 8.4 Pediatric Use Safety and effectiveness of cabergoline tablets in pediatric patients have not been established.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "When using cabergoline tablets in patients with moderate HI (Child-Pugh B) increase monitoring of cabergoline tablets-associated adverse reactions.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ],
    "pregnancy": [
      {
        "text": "Risk Summary If conception occurs during cabergoline tablets therapy, discontinue cabergoline tablets if the risks to the mother or fetus outweigh the benefits to the mother.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "There are risks to the mother associated with the use of cabergoline tablets ( see Clinical Considerations ).",
        "source": "US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "The estimated background risk of major birth defects and miscarriage in patients with hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas is unknown.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'pregnancy', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ],
    "lactation": [
      {
        "text": "However, in another study in rabbits, no treatment-related malformations or embryofetal toxicity were observed at doses up to 8 mg/kg/day (approximately 300 times the maximum recommended human dose). 8.2 Lactation Risk Summary Cabergoline tablets are not recommended in postpartum women who are breastfeeding or who are planning to breastfeed.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      },
      {
        "text": "Avoid use of cabergoline tablets for the inhibition or suppression of physiologic lactation [see Indications and Usage ( 1 ) and Warnings and Precautions ( 5 . 4 )] . 8.4 Pediatric Use Safety and effectiveness of cabergoline tablets in pediatric patients have not been established.",
        "source": "US FDA label for cabergoline (Cabergoline), section 'use in specific populations', retrieved 2026-08-29",
        "cached_file": "labels/cabergoline.json",
        "verbatim": true
      }
    ]
  }
}